{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:07:19Z","timestamp":1784012839273,"version":"3.55.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00520-026-10913-6","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:04:58Z","timestamp":1782180298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The burden of cardiovascular disease in prostate cancer: prevalence, pathophysiology, and implications for integrated care"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9465-0089","authenticated-orcid":false,"given":"Ikponmwosa Jude","family":"Ogieuhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chidera Stanley","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Oluwatomiwa","family":"Ajekiigbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajao Favour","family":"Ayomikun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efosa Peace","family":"Iyawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Abiodun","family":"Adegbesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganiyat Adekemi","family":"Adeshina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahmon","family":"Moradeyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adewunmi","family":"Akingbola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayode Emmanuel","family":"Ogunniyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"10913_CR1","doi-asserted-by":"crossref","unstructured":"Sooraj Kakkat, Paramahansa Pramanik, Singh S, Singh AP, Sarkar C, Debanjan Chakroborty (2023) Cardiovascular complications in patients with prostate cancer: potential molecular connections. Int J Mol Sci 24(8):6984\u20134","DOI":"10.3390\/ijms24086984"},{"key":"10913_CR2","doi-asserted-by":"crossref","unstructured":"Mohamed NA (2019) Prevalence of risk factors for diabetes mellitus and hypertension among adult in Tabuk - Kingdom of Saudi Arabia. Open Access Maced J Med Sci 7(5):831\u2013837","DOI":"10.3889\/oamjms.2019.046"},{"key":"10913_CR3","doi-asserted-by":"publisher","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fern\u00e1ndez-Sol\u00e0 J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundstr\u00f6m J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group (2020) Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 Study. J Am Coll Cardiol 76(25):2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010. Erratum in: J Am Coll Cardiol. 2021 Apr 20;77(15):1958\u20131959. 10.1016\/j.jacc.2021.02.039","DOI":"10.1016\/j.jacc.2020.11.010"},{"key":"10913_CR4","unstructured":"Leslie SW, Soon-Sutton TL, Sajjad H, Siref LE (2023) Prostate cancer [Internet]. StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470550\/. Accessed 20 Jun 2026"},{"key":"10913_CR5","unstructured":"Gallagher K (2024) Prostate cancer cases expected to double worldwide between 2020 and 2040, new analysis suggests [Internet]. Prostate Cancer Foundation. Available from: https:\/\/www.pcf.org\/news\/prostate-cancer-cases-expected-to-double-worldwide-between-2020-and-2040-new-analysis-suggests\/. Accessed 20 Jun 2026"},{"key":"10913_CR6","doi-asserted-by":"publisher","unstructured":"Moryousef J, Duivenvoorden W, Leong D, Pinthus JH (2025) Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies. Prostate Cancer Prostatic Dis 28(3):632\u2013638. https:\/\/doi.org\/10.1038\/s41391-024-00897-x","DOI":"10.1038\/s41391-024-00897-x"},{"key":"10913_CR7","doi-asserted-by":"publisher","unstructured":"Hu JR, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, Salem JE, Beckman JA, Moslehi JJ (2020) Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler Thromb Vasc Biol 40(3):e55-e64. https:\/\/doi.org\/10.1161\/ATVBAHA.119.313046","DOI":"10.1161\/ATVBAHA.119.313046"},{"key":"10913_CR8","unstructured":"National Cancer Institute (2019) Prostate cancer [Internet]. National Cancer Institute. Available from: https:\/\/www.cancer.gov\/types\/prostate. Accessed 20 Jun 2026"},{"issue":"9","key":"10913_CR9","doi-asserted-by":"publisher","first-page":"E458","DOI":"10.5489\/cuaj.6685","volume":"14","author":"M Kenk","year":"2020","unstructured":"Kenk M, Gr\u00e9goire JC, Cot\u00e9 MA, Connelly KA, Davis MK, Dresser G, Ghosh N, Goodman S, Johnson C, Fleshner N (2020) Optimizing screening and management of cardiovascular health in prostate cancer: a review. Can Urol Assoc J 14(9):E458\u2013E464. https:\/\/doi.org\/10.5489\/cuaj.6685","journal-title":"Can Urol Assoc J"},{"key":"10913_CR10","doi-asserted-by":"publisher","unstructured":"Zhou S, Alerasool P, Kishi N, Joshi H, Sahni G, Tsao CK (2024) Cardiovascular toxicity associated with androgen receptor axis-targeted agents in patients with prostate cancer: a meta-analysis of randomized controlled trials. Clin Genitourin Cancer 22(3):102066. https:\/\/doi.org\/10.1016\/j.clgc.2024.102066","DOI":"10.1016\/j.clgc.2024.102066"},{"issue":"7","key":"10913_CR11","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","volume":"10","author":"O El-Taji","year":"2024","unstructured":"El-Taji O, Taktak S, Jones C, Brown M, Clarke N, Sachdeva A (2024) Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis. JAMA Oncol 10(7):874\u2013884. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1549","journal-title":"JAMA Oncol"},{"issue":"2","key":"10913_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41391-024-00886-0","volume":"28","author":"A Matsukawa","year":"2025","unstructured":"Matsukawa A, Yanagisawa T, Parizi MK, Laukhtina E, Klemm J, Fazekas T, Mori K, Kimura S, Briganti A, Ploussard G, Karakiewicz PI, Miki J, Kimura T, Rajwa P, Shariat SF (2025) Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. Prostate Cancer Prostatic Dis 28(2):298\u2013308. https:\/\/doi.org\/10.1038\/s41391-024-00886-0","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"10913_CR13","doi-asserted-by":"publisher","first-page":"e51038","DOI":"10.7759\/cureus.51038","volume":"15","author":"R Sharma","year":"2023","unstructured":"Sharma R, Kashyap J, Olanrewaju OA, Jabbar A, Someshwar F, Saeed H, Varrassi G, Qadeer HA, Kumar S, Cheema AY, Khatri M, Wazir M, Ullah F (2023) Cardio-oncology: managing cardiovascular complications of cancer therapies. Cureus 15(12):e51038. https:\/\/doi.org\/10.7759\/cureus.51038","journal-title":"Cureus"},{"key":"10913_CR14","doi-asserted-by":"publisher","unstructured":"Fazekas T, Miszczyk M, Giesen A, K\u00f3i T, Zattoni F, Rodriguez-Sanchez L, Yanagisawa T, Matsukawa A, Szarvas T, Kryst P, G\u00f3mez Rivas J, Merseburger AS, De Santis M, Joniau S, Briganti A, Marra G, Nyir\u00e1dy P, Gandaglia G, Shariat SF, Rajwa P; EAU-YAU Prostate Cancer Working Group (2026) Androgen receptor pathway inhibitor monotherapy in prostate cancer: safety, oncologic outcomes, and quality of life\u2014a systematic review and meta-analysis. Eur Urol Focus 12(1):109\u2013130. https:\/\/doi.org\/10.1016\/j.euf.2025.05.006","DOI":"10.1016\/j.euf.2025.05.006"},{"key":"10913_CR15","doi-asserted-by":"publisher","unstructured":"Korhonen MJ, Pentti J, Hartikainen J, Ilom\u00e4ki J, Setoguchi S, Liew D, Kivim\u00e4ki M, Vahtera J (2020) Lifestyle changes in relation to initiation of antihypertensive and lipid-lowering medication: a cohort study. J Am Heart Assoc 9(4):e014168. https:\/\/doi.org\/10.1161\/JAHA.119.014168","DOI":"10.1161\/JAHA.119.014168"},{"issue":"1","key":"10913_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/medicina60010077","volume":"60","author":"AB Reiss","year":"2023","unstructured":"Reiss AB, Gulkarov S, Pinkhasov A, Sheehan KM, Srivastava A, De Leon J, Katz AE (2023) Androgen deprivation therapy for prostate cancer: focus on cognitive function and mood. Medicina (Kaunas) 60(1):77. https:\/\/doi.org\/10.3390\/medicina60010077","journal-title":"Medicina (Kaunas)"},{"key":"10913_CR17","doi-asserted-by":"publisher","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, Bray F, Brawley O, Luckenbaugh AN, Mucci L, Morgan TM, Carlsson SV (2023) 2022 Update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol 84(2):191\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021","DOI":"10.1016\/j.eururo.2023.04.021"},{"issue":"11","key":"10913_CR18","doi-asserted-by":"publisher","first-page":"102785","DOI":"10.1016\/j.cpcardiol.2024.102785","volume":"49","author":"A Ahad","year":"2024","unstructured":"Ahad A, Ejaz A, Fatima E, Sultan W, Ahmad O, Jamil A (2024) Rising mortality related to cardiovascular disease and prostate cancer amongst older men across the United States. Curr Probl Cardiol 49(11):102785","journal-title":"Curr Probl Cardiol"},{"key":"10913_CR19","doi-asserted-by":"crossref","unstructured":"Giona S (2021) The epidemiology of prostate cancer. In: Prostate cancer [Internet]. Frimley Park Hospital. Available from:  https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK571326\/. Accessed 20 Jun 2026","DOI":"10.36255\/exonpublications.prostatecancer.epidemiology.2021"},{"issue":"6","key":"10913_CR20","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jaccao.2024.09.005","volume":"6","author":"DP Leong","year":"2024","unstructured":"Leong DP, Guha A, Morgans AK, Niazi T, Pinthus JH (2024) Cardiovascular risk in prostate cancer: JACC: CardioOncology state-of-the-art review. J Am Coll Cardiol CardioOnc 6(6):835\u2013846. https:\/\/doi.org\/10.1016\/j.jaccao.2024.09.005","journal-title":"J Am Coll Cardiol CardioOnc"},{"key":"10913_CR21","doi-asserted-by":"publisher","unstructured":"Alzahrani AM, Al Shamsi H, Al Momen M, Al Fluij A, Al Matar A (2024) Prevalence of preexisting cardiovascular diseases in prostate cancer patients and cardiac risks of hormonal therapy. Saudi J Med Med Sci 12(1):60\u201364. https:\/\/doi.org\/10.4103\/sjmms.sjmms_150_23","DOI":"10.4103\/sjmms.sjmms_150_23"},{"key":"10913_CR22","doi-asserted-by":"publisher","unstructured":"Kaneta K, Tanaka A, Nakai M, Sumita Y, Kaneko H, Noguchi M, Node K (2023) Prevalence and temporal trends of prostate diseases among inpatients with cardiovascular disease: a nationwide real-world database survey in Japan. Front Cardiovasc Med 10. https:\/\/doi.org\/10.3389\/fcvm.2023.1236144","DOI":"10.3389\/fcvm.2023.1236144"},{"issue":"8","key":"10913_CR23","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.3390\/cancers15082316","volume":"15","author":"J Fradin","year":"2023","unstructured":"Fradin J, Kim FJ, Lu-Yao GL, Storozynsky E, Kelly WK (2023) Review of cardiovascular risk of androgen deprivation therapy and the influence of race in men with prostate cancer. Cancers (Basel) 15(8):2316. https:\/\/doi.org\/10.3390\/cancers15082316","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10913_CR24","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","volume":"121","author":"GN Levine","year":"2010","unstructured":"Levine GN, D\u2019Amico AV, Berger P, Clark PE, Eckel RH, Keating NL (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk. Circulation 121(6):833\u2013840","journal-title":"Circulation"},{"key":"10913_CR25","doi-asserted-by":"crossref","unstructured":"Ruth A.L. Willems, Kristien Winckers, Biesmans C, Judith de Vos\u2010Geelen, Hugo Ten Cate (2022) Evolving data on cardiovascular complications in cancer. Thrombos Res 213:S87\u201394","DOI":"10.1016\/j.thromres.2022.01.003"},{"key":"10913_CR26","doi-asserted-by":"publisher","unstructured":"Choi S, Lee AK (2011) Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. Drug Healthc Patient Saf 3:107\u201319. https:\/\/doi.org\/10.2147\/DHPS.S24106","DOI":"10.2147\/DHPS.S24106"},{"key":"10913_CR27","doi-asserted-by":"publisher","unstructured":"Campbell CM, Zhang KW, Collier A et al (2020) Cardiovascular complications of prostate cancer therapy. Curr Treat Options Cardio Med 22:69. https:\/\/doi.org\/10.1007\/s11936-020-00873-3","DOI":"10.1007\/s11936-020-00873-3"},{"issue":"11","key":"10913_CR28","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH (2016) Shared risk factors in cardiovascular disease and cancer. Circulation 133(11):1104\u20131114. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.020406","journal-title":"Circulation"},{"issue":"4","key":"10913_CR29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jaccao.2023.03.016","volume":"5","author":"CA Lin","year":"2023","unstructured":"Lin CA, Kao YS (2023) Prostate cancer and cardiovascular risk factors. JACC CardioOncol 5(4):551. https:\/\/doi.org\/10.1016\/j.jaccao.2023.03.016","journal-title":"JACC CardioOncol"},{"issue":"5","key":"10913_CR30","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386. https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"key":"10913_CR31","doi-asserted-by":"publisher","unstructured":"Mensah GA, Fuster V, Murray CJL, Roth GA; Global Burden of Cardiovascular Diseases and Risks Collaborators (2023) Global burden of cardiovascular diseases and risks, 1990\u20132022. J Am Coll Cardiol 82(25):2350\u20132473. https:\/\/doi.org\/10.1016\/j.jacc.2023.11.007","DOI":"10.1016\/j.jacc.2023.11.007"},{"key":"10913_CR32","doi-asserted-by":"publisher","first-page":"e390396","DOI":"10.1200\/EDBK_390396","volume":"43","author":"LS Graham","year":"2023","unstructured":"Graham LS, Lin JK, Lage DE, Kessler ER, Parikh RB, Morgans AK (2023) Management of prostate cancer in older adults. Am Soc Clin Oncol Educ Book 43:e390396. https:\/\/doi.org\/10.1200\/EDBK_390396","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10913_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/jcdd6020019","volume":"6","author":"JL Rodgers","year":"2019","unstructured":"Rodgers JL, Jones J, Bolleddu SI, Vanthenapalli S, Rodgers LE, Shah K, Karia K, Panguluri SK (2019) Cardiovascular risks associated with gender and aging. J Cardiovasc Dev Dis 6(2):19. https:\/\/doi.org\/10.3390\/jcdd6020019","journal-title":"J Cardiovasc Dev Dis"},{"issue":"29","key":"10913_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.omto.2023.04.007","volume":"29","author":"M Lin","year":"2023","unstructured":"Lin M, Sun X, Lv L (2023) New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer. Mol Ther Oncolytics 29(29):91\u2013106. https:\/\/doi.org\/10.1016\/j.omto.2023.04.007","journal-title":"Mol Ther Oncolytics"},{"issue":"6","key":"10913_CR35","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.3390\/jcm9061995","volume":"9","author":"MG Scioli","year":"2020","unstructured":"Scioli MG, Storti G, D\u2019Amico F, Rodr\u00edguez Guzm\u00e1n R, Centofanti F, Doldo E, C\u00e9spedes Miranda EM, Orlandi A (2020) Oxidative stress and new pathogenetic mechanisms in endothelial dysfunction: potential diagnostic biomarkers and therapeutic targets. J Clin Med 9(6):1995. https:\/\/doi.org\/10.3390\/jcm9061995","journal-title":"J Clin Med"},{"key":"10913_CR36","doi-asserted-by":"publisher","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, Despr\u00e9s JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council (2021) Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 143(21):e984-e1010. https:\/\/doi.org\/10.1161\/CIR.0000000000000973","DOI":"10.1161\/CIR.0000000000000973"},{"issue":"10","key":"10913_CR37","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41585-023-00764-9","volume":"20","author":"A Saha","year":"2023","unstructured":"Saha A, Kolonin MG, DiGiovanni J (2023) Obesity and prostate cancer - microenvironmental roles of adipose tissue. Nat Rev Urol 20(10):579\u2013596. https:\/\/doi.org\/10.1038\/s41585-023-00764-9","journal-title":"Nat Rev Urol"},{"key":"10913_CR38","doi-asserted-by":"publisher","first-page":"103543","DOI":"10.1016\/j.critrevonc.2021.103543","volume":"169","author":"RL Wilson","year":"2022","unstructured":"Wilson RL, Taaffe DR, Newton RU, Hart NH, Lyons-Wall P, Galv\u00e3o DA (2022) Obesity and prostate cancer: a narrative review. Crit Rev Oncol Hematol 169:103543. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103543","journal-title":"Crit Rev Oncol Hematol"},{"key":"10913_CR39","doi-asserted-by":"publisher","unstructured":"Hopkins BD, Goncalves MD, Cantley LC (2016) Obesity and cancer mechanisms: cancer metabolism. J Clin Oncol 34(35):4277\u20134283. https:\/\/doi.org\/10.1200\/JCO.2016.67.9712","DOI":"10.1200\/JCO.2016.67.9712"},{"key":"10913_CR40","doi-asserted-by":"publisher","unstructured":"Friedenreich CM, Ryder-Burbidge C, McNeil J (2021) Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol Oncol 15(3):790\u2013800. https:\/\/doi.org\/10.1002\/1878-0261.12772","DOI":"10.1002\/1878-0261.12772"},{"issue":"1","key":"10913_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.11124\/JBIES-22-00356","volume":"22","author":"JK Kariuki","year":"2024","unstructured":"Kariuki JK, Imes CC, Engberg SJ, Scott PW, Klem ML, Cortes YI (2024) Impact of lifestyle-based interventions on absolute cardiovascular disease risk: a systematic review and meta-analysis. JBI Evid Synth 22(1):4\u201365. https:\/\/doi.org\/10.11124\/JBIES-22-00356","journal-title":"JBI Evid Synth"},{"key":"10913_CR42","doi-asserted-by":"publisher","unstructured":"Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM (2011) Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 29(6):726\u201332. https:\/\/doi.org\/10.1200\/JCO.2010.31.5226","DOI":"10.1200\/JCO.2010.31.5226"},{"issue":"2","key":"10913_CR43","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/nu13020496","volume":"13","author":"M Oczkowski","year":"2021","unstructured":"Oczkowski M, Dziendzikowska K, Pasternak-Winiarska A, W\u0142odarek D, Gromadzka-Ostrowska J (2021) Dietary factors and prostate cancer development, progression, and reduction. Nutrients 13(2):496. https:\/\/doi.org\/10.3390\/nu13020496","journal-title":"Nutrients"},{"issue":"13","key":"10913_CR44","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.3390\/nu14132649","volume":"14","author":"E Szczepa\u0144ska","year":"2022","unstructured":"Szczepa\u0144ska E, Bia\u0142ek-Dratwa A, Janota B, Kowalski O (2022) Dietary therapy in prevention of cardiovascular disease (CVD)-tradition or modernity? A review of the latest approaches to nutrition in CVD. Nutrients 14(13):2649. https:\/\/doi.org\/10.3390\/nu14132649","journal-title":"Nutrients"},{"key":"10913_CR45","doi-asserted-by":"publisher","unstructured":"Widmer RJ, Flammer AJ, Lerman LO, Lerman A (2015) The Mediterranean diet, its components, and cardiovascular disease. Am J Med 128(3):229\u201338. https:\/\/doi.org\/10.1016\/j.amjmed.2014.10.014","DOI":"10.1016\/j.amjmed.2014.10.014"},{"issue":"9","key":"10913_CR46","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.3390\/nu11092059","volume":"11","author":"MC Mentella","year":"2019","unstructured":"Mentella MC, Scaldaferri F, Ricci C, Gasbarrini A, Miggiano GAD (2019) Cancer and Mediterranean diet: a review. Nutrients 11(9):2059. https:\/\/doi.org\/10.3390\/nu11092059","journal-title":"Nutrients"},{"issue":"3","key":"10913_CR47","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/01.ju.0000169487.49018.73","volume":"174","author":"D Ornish","year":"2005","unstructured":"Ornish D, Weidner G, Fair WR (2005) Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 174(3):1065\u20131070. https:\/\/doi.org\/10.1097\/01.ju.0000169487.49018.73","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10913_CR48","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.reuma.2008.12.008","volume":"5","author":"F Vidal-Vanaclocha","year":"2009","unstructured":"Vidal-Vanaclocha F (2009) Inflammation in the molecular pathogenesis of cancer and atherosclerosis. Reumatol Clin 5(Suppl 1):40\u201343. https:\/\/doi.org\/10.1016\/j.reuma.2008.12.008","journal-title":"Reumatol Clin"},{"key":"10913_CR49","doi-asserted-by":"publisher","unstructured":"Valle LF, Jiang T, Weiner AB, Reiter RE, Rettig MB, Shen J, Chang AJ, Nickols NG, Steinberg ML, Kishan AU (2023) Multimodality therapies for localized prostate cancer. Curr Oncol Rep 25(3):221\u2013229. https:\/\/doi.org\/10.1007\/s11912-023-01374-9","DOI":"10.1007\/s11912-023-01374-9"},{"key":"10913_CR50","doi-asserted-by":"publisher","unstructured":"Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB (2015) Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol 67(3):470\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2014.09.049","DOI":"10.1016\/j.eururo.2014.09.049"},{"key":"10913_CR51","doi-asserted-by":"publisher","unstructured":"Kim J, Freeman K, Ayala A, Mullen M, Sun Z, Rhee JW (2023) Cardiovascular impact of androgen deprivation therapy: from basic biology to clinical practice. Curr Oncol Rep 25(9):965\u2013977. https:\/\/doi.org\/10.1007\/s11912-023-01424-2","DOI":"10.1007\/s11912-023-01424-2"},{"issue":"1","key":"10913_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.eururo.2020.06.002","volume":"79","author":"M Abufaraj","year":"2021","unstructured":"Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, Moschini M, Briganti A, Karakiewicz PI, Shariat SF (2021) Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials. Eur Urol 79(1):44\u201353. https:\/\/doi.org\/10.1016\/j.eururo.2020.06.002","journal-title":"Eur Urol"},{"key":"10913_CR53","doi-asserted-by":"publisher","unstructured":"Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B (2020) HERO Study investigators. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 382(23):2187\u20132196. https:\/\/doi.org\/10.1056\/NEJMoa2004325","DOI":"10.1056\/NEJMoa2004325"},{"key":"10913_CR54","doi-asserted-by":"publisher","unstructured":"Patel SA, Yadalam AK, van Assen M et al (2026) Coronary plaque progression after androgen deprivation therapy in men with prostate cancer: a randomized clinical trial. JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2025.5586.Published online February 18, 2026.","DOI":"10.1001\/jamacardio.2025.5586"},{"issue":"2018","key":"10913_CR55","doi-asserted-by":"publisher","first-page":"1414395","DOI":"10.1155\/2018\/1414395","volume":"16","author":"Y Yamamoto","year":"2018","unstructured":"Yamamoto Y, Akashi Y, Minami T, Nozawa M, Kiba K, Yoshikawa M, Hirayama A, Uemura H (2018) Serious hypokalemia associated with abiraterone acetate in patients with castration-resistant prostate cancer. Case Rep Urol 16(2018):1414395. https:\/\/doi.org\/10.1155\/2018\/1414395","journal-title":"Case Rep Urol"},{"issue":"1","key":"10913_CR56","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/ERC-18-0289","volume":"26","author":"S Linder","year":"2018","unstructured":"Linder S, van der Poel HG, Bergman AM, Zwart W, Prekovic S (2018) Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. Endocr Relat Cancer 26(1):R31\u2013R52. https:\/\/doi.org\/10.1530\/ERC-18-0289","journal-title":"Endocr Relat Cancer"},{"key":"10913_CR57","doi-asserted-by":"publisher","unstructured":"Nabia\u0142ek-Trojanowska I, Lewicka E, Wrona A, Kaleta AM, Lewicka-Potocka Z, Raczak G, Dziadziuszko R (2020) Cardiovascular complications after radiotherapy. Cardiol J 27(6):836\u2013847. https:\/\/doi.org\/10.5603\/CJ.a2018.0120","DOI":"10.5603\/CJ.a2018.0120"},{"issue":"5","key":"10913_CR58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fcvm.2018.00005","volume":"31","author":"CB Sylvester","year":"2018","unstructured":"Sylvester CB, Abe JI, Patel ZS, Grande-Allen KJ (2018) Radiation-induced cardiovascular disease: mechanisms and importance of linear energy transfer. Front Cardiovasc Med 31(5):5. https:\/\/doi.org\/10.3389\/fcvm.2018.00005","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10913_CR59","doi-asserted-by":"publisher","first-page":"251","DOI":"10.7861\/clinmed.2021-0600","volume":"22","author":"A Kirresh","year":"2022","unstructured":"Kirresh A, White L, Mitchell A, Ahmad S, Obika B, Davis S, Ahmad M, Candilio L (2022) Radiation-induced coronary artery disease: a difficult clinical conundrum. Clin Med (Lond) 22(3):251\u2013256. https:\/\/doi.org\/10.7861\/clinmed.2021-0600","journal-title":"Clin Med (Lond)"},{"issue":"3","key":"10913_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11912-021-01014-0","volume":"23","author":"AM Joshi","year":"2021","unstructured":"Joshi AM, Prousi GS, Bianco C, Malla M, Guha A, Shah M, Brown SA, Patel B (2021) Microtubule inhibitors and cardiotoxicity. Curr Oncol Rep 23(3):30. https:\/\/doi.org\/10.1007\/s11912-021-01014-0","journal-title":"Curr Oncol Rep"},{"issue":"18","key":"10913_CR61","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2217\/pgs-2021-0119","volume":"22","author":"T Ziadeh","year":"2021","unstructured":"Ziadeh T, Kourie HR (2021) Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology. Pharmacogenomics 22(18):1237\u20131250. https:\/\/doi.org\/10.2217\/pgs-2021-0119","journal-title":"Pharmacogenomics"},{"key":"10913_CR62","doi-asserted-by":"publisher","unstructured":"Zhang X, Pan J, Xu R, Fu Y, Lv B (2024) Erectile dysfunction associated with prostate cancer treatment and therapeutic advances: a narrative review. Transl Androl Urol 13(11):2625\u20132643. https:\/\/doi.org\/10.21037\/tau-24-514","DOI":"10.21037\/tau-24-514"},{"key":"10913_CR63","doi-asserted-by":"crossref","unstructured":"Gryzinski GM, Fustok J, Raheem OA (2022) Sexual function in men undergoing androgen deprivation therapy. Androgens: Clin Res Ther 3:149\u201358. [Google Scholar]","DOI":"10.1089\/andro.2022.0002"},{"issue":"12","key":"10913_CR64","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.3390\/life13122337","volume":"13","author":"SC Latcu","year":"2023","unstructured":"Latcu SC, Novacescu D, Buciu V, Dumitru C, Ceausu RA, Raica M, Cut TG, Ilina R, Malita DC, Tarta C, Cumpanas AA (2023) The cavernous nerve injury rat model: a pictorial essay on post-radical prostatectomy erectile dysfunction research. Life 13(12):2337. https:\/\/doi.org\/10.3390\/life13122337","journal-title":"Life"},{"issue":"10","key":"10913_CR65","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.3390\/jcm10102221","volume":"10","author":"D Yannas","year":"2021","unstructured":"Yannas D, Frizza F, Vignozzi L, Corona G, Maggi M, Rastrelli G (2021) Erectile dysfunction is a hallmark of cardiovascular disease: unavoidable matter of fact or opportunity to improve men\u2019s health? J Clin Med 10(10):2221. https:\/\/doi.org\/10.3390\/jcm10102221","journal-title":"J Clin Med"},{"key":"10913_CR66","doi-asserted-by":"publisher","unstructured":"Almuqahwi A, Alabdrabulridha H, Aljumaiah RM, Alfaifi AJ, Alnaim MF, Alfaifi IA, Alsaleh NA, Abdullah Alsalem N, Alsuwaylih F, Ahmed Ali Almana A, Altaweel FI, Alsalman SM, AlAli Y (2023) A systematic review on the relationship between physical activity and sexual function in adults. Cureus 15(12):e51307. https:\/\/doi.org\/10.7759\/cureus.51307","DOI":"10.7759\/cureus.51307"},{"issue":"9","key":"10913_CR67","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/cncr.35172","volume":"130","author":"S Loeb","year":"2024","unstructured":"Loeb S, Hua Q, Bauer SR, Kenfield SA, Morgans AK, Chan JM, Van Blarigan EL, Shreves AH, Mucci LA (2024) Plant-based diet associated with better quality of life in prostate cancer survivors. Cancer 130(9):1618\u20131628. https:\/\/doi.org\/10.1002\/cncr.35172","journal-title":"Cancer"},{"issue":"22","key":"10913_CR68","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1182\/bloodadvances.2019000369","volume":"3","author":"H Al-Samkari","year":"2019","unstructured":"Al-Samkari H, Connors JM (2019) Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Blood Adv 3(22):3770\u20133779. https:\/\/doi.org\/10.1182\/bloodadvances.2019000369","journal-title":"Blood Adv"},{"key":"10913_CR69","doi-asserted-by":"publisher","unstructured":"Beavers CJ, Rodgers JE, Bagnola AJ, Beckie TM, Campia U, Di Palo KE, Okwuosa TM, Przespolewski ER, Dent S; American Heart Association Clinical Pharmacology Committee and Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; and the Council on Peripheral Vascular Disease (2022) Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation 145(15):e811-e838. https:\/\/doi.org\/10.1161\/CIR.0000000000001056","DOI":"10.1161\/CIR.0000000000001056"},{"key":"10913_CR70","doi-asserted-by":"publisher","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K; ESMO Guidelines Committee (2020) Electronic address: clinicalguidelines@esmo.org. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 31(2):171\u2013190. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.023","DOI":"10.1016\/j.annonc.2019.10.023"},{"key":"10913_CR71","doi-asserted-by":"publisher","first-page":"e18851","DOI":"10.1200\/JCO.2023.41.16_suppl.e18851","volume":"41","author":"MA Saidi","year":"2023","unstructured":"Saidi MA, Ghomari S, Sarra S (2023) Cardiovascular comorbidities and cardiovascular events in patients with metastatic prostate cancer. J Clin Oncol 41:e18851\u2013e18851. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e18851","journal-title":"J Clin Oncol"},{"issue":"32","key":"10913_CR72","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2016.71.4204","volume":"35","author":"DY Chen","year":"2017","unstructured":"Chen DY, See LC, Liu JR, Chuang CK, Pang ST, Hsieh IC, Wen MS, Chen TH, Lin YC, Liaw CC, Hsu CL, Chang JW, Kuo CF, Huang WK (2017) Risk of cardiovascular ischemic events after surgical castration and gonadotropin-releasing hormone agonist therapy for prostate cancer: a nationwide cohort study. J Clin Oncol 35(32):3697\u20133705. https:\/\/doi.org\/10.1200\/JCO.2016.71.4204","journal-title":"J Clin Oncol"},{"issue":"2","key":"10913_CR73","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000521680","volume":"147","author":"KD Boudoulas","year":"2022","unstructured":"Boudoulas KD, Triposkiadis F, Gumina R, Addison D, Iliescu C, Boudoulas H (2022) Cardiovascular disease, cancer, and multimorbidity interactions: clinical implications. Cardiology 147(2):196\u2013206","journal-title":"Cardiology"},{"issue":"12","key":"10913_CR74","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.urolonc.2020.07.004","volume":"38","author":"CS Higano","year":"2020","unstructured":"Higano CS (2020) Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer. Urol Oncol 38(12):912\u2013917. https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.004","journal-title":"Urol Oncol"},{"issue":"1","key":"10913_CR75","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.critrevonc.2012.10.007","volume":"86","author":"V Conteduca","year":"2013","unstructured":"Conteduca V, Di Lorenzo G, Tartarone A, Aieta M (2013) The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Crit Rev Oncol Hematol 86(1):42\u201351. https:\/\/doi.org\/10.1016\/j.critrevonc.2012.10.007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10913_CR76","doi-asserted-by":"publisher","first-page":"555475","DOI":"10.3389\/fphar.2020.555475","volume":"11","author":"M Wilk","year":"2020","unstructured":"Wilk M, Wa\u015bko-Grabowska A, Szmit S (2020) Cardiovascular complications of prostate cancer treatment. Front Pharmacol 11:555475. https:\/\/doi.org\/10.3389\/fphar.2020.555475","journal-title":"Front Pharmacol"},{"issue":"5","key":"10913_CR77","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/curroncol28050289","volume":"28","author":"GS Gheorghe","year":"2021","unstructured":"Gheorghe GS, Hodorogea AS, Ciobanu A, Nanea IT, Gheorghe ACD (2021) Androgen deprivation therapy, hypogonadism, and cardiovascular toxicity in men with advanced prostate cancer. Curr Oncol 28(5):289. https:\/\/doi.org\/10.3390\/curroncol28050289","journal-title":"Curr Oncol"},{"issue":"11","key":"10913_CR78","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/JCO.2014.59.1792","volume":"33","author":"S O'Farrell","year":"2015","unstructured":"O\u2019Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33(11):1231\u20131237. https:\/\/doi.org\/10.1200\/JCO.2014.59.1792","journal-title":"J Clin Oncol"},{"key":"10913_CR79","doi-asserted-by":"publisher","unstructured":"Campodonico F, Foppiani L, Campodonico V, Introini C (2024) Practical implications of androgen receptor inhibitors for prostate cancer treatment. ETAT 00234. https:\/\/doi.org\/10.37349\/etat.2024.00234","DOI":"10.37349\/etat.2024.00234"},{"issue":"9","key":"10913_CR80","doi-asserted-by":"publisher","first-page":"7883","DOI":"10.1074\/jbc.M411694200","volume":"280","author":"Y Ikeda","year":"2005","unstructured":"Ikeda Y, Aihara K-I, Sato T, Akaike M, Yoshizumi M, Suzaki Y, Izawa Y, Fujimura M, Hashizume S, Kato M, Yagi S, Tamaki T, Kawano H, Matsumoto T, Azuma H, Kato S, Matsumoto T (2005) Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem 280(9):7883\u20137890. https:\/\/doi.org\/10.1074\/jbc.M411694200","journal-title":"J Biol Chem"},{"issue":"3","key":"10913_CR81","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ando.2020.02.008","volume":"8","author":"JE Salem","year":"2020","unstructured":"Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, Hidden-Lucet F, Hulot JS, Knollmann BC, Lebrun-Vignes B, Funck-Brentano C, Glazer AM, Roden DM (2020) Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Andrology 8(3):604\u2013612. https:\/\/doi.org\/10.1016\/j.ando.2020.02.008","journal-title":"Andrology"},{"issue":"10","key":"10913_CR82","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/07357907.2019.1670203","volume":"37","author":"X Zhu","year":"2019","unstructured":"Zhu X, Wu S (2019) Increased risk of hypertension with enzalutamide in prostate cancer: a meta-analysis. Cancer Invest 37(10):541\u2013548. https:\/\/doi.org\/10.1080\/07357907.2019.1670203","journal-title":"Cancer Invest"},{"issue":"3","key":"10913_CR83","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1210\/jc.2011-2189","volume":"97","author":"G Attard","year":"2012","unstructured":"Attard G, Reid AHM, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, de Bono JS (2012) Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 97(3):830\u2013839. https:\/\/doi.org\/10.1210\/jc.2011-2189","journal-title":"J Clin Endocrinol Metab"},{"key":"10913_CR84","doi-asserted-by":"publisher","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K; the COU-AA-302 Investigators (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. New Engl J Med 368(2):138\u2013148. https:\/\/doi.org\/10.1056\/NEJMoa1209096","DOI":"10.1056\/NEJMoa1209096"},{"issue":"4","key":"10913_CR85","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(05)70094-2","volume":"6","author":"A Montero","year":"2005","unstructured":"Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6(4):229\u2013239. https:\/\/doi.org\/10.1016\/S1470-2045(05)70094-2","journal-title":"Lancet Oncol"},{"issue":"1","key":"10913_CR86","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/toxsci\/kfv017","volume":"143","author":"C-H Hung","year":"2015","unstructured":"Hung C-H, Chan S-H, Chu P-M, Tsai K-L (2015) Docetaxel facilitates endothelial dysfunction through oxidative stress via modulation of protein kinase C beta: the protective effects of sotrastaurin. Toxicol Sci 143(1):166\u2013176. https:\/\/doi.org\/10.1093\/toxsci\/kfv017","journal-title":"Toxicol Sci"},{"key":"10913_CR87","doi-asserted-by":"publisher","first-page":"592746","DOI":"10.3389\/fonc.2020.592746","volume":"10","author":"Y Guo","year":"2020","unstructured":"Guo Y, Dong X, Yang F, Yu Y, Wang R, Kadier A, Zhang W, Mao S, Zhang A, Yao X (2020) Effects of radiotherapy or radical prostatectomy on the risk of long-term heart-specific death in patients with prostate cancer. Front Oncol 10:592746. https:\/\/doi.org\/10.3389\/fonc.2020.592746","journal-title":"Front Oncol"},{"issue":"7","key":"10913_CR88","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S1470-2045(09)70082-8","volume":"10","author":"SC Formenti","year":"2009","unstructured":"Formenti SC, Demaria S (2009) Systemic effects of local radiotherapy. Lancet Oncol 10(7):718\u2013726. https:\/\/doi.org\/10.1016\/S1470-2045(09)70082-8","journal-title":"Lancet Oncol"},{"issue":"11","key":"10913_CR89","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/nrc1735","volume":"5","author":"MH Barcellos-Hoff","year":"2005","unstructured":"Barcellos-Hoff MH, Park C, Wright EG (2005) Radiation and the microenvironment\u2014tumorigenesis and therapy. Nat Rev Cancer 5(11):867\u2013875. https:\/\/doi.org\/10.1038\/nrc1735","journal-title":"Nat Rev Cancer"},{"issue":"48","key":"10913_CR90","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.1038\/sj.onc.1204749","volume":"20","author":"SA Lorimore","year":"2001","unstructured":"Lorimore SA, Coates PJ, Scobie GE, Milne G, Wright EG (2001) Inflammatory-type responses after exposure to ionizing radiation in vivo: a mechanism for radiation-induced bystander effects? Oncogene 20(48):7085\u20137095. https:\/\/doi.org\/10.1038\/sj.onc.1204749","journal-title":"Oncogene"},{"issue":"3","key":"10913_CR91","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/01.cir.0000052939.59093.45","volume":"107","author":"TA Pearson","year":"2003","unstructured":"Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107(3):499\u2013511. https:\/\/doi.org\/10.1161\/01.cir.0000052939.59093.45","journal-title":"Circulation"},{"issue":"3","key":"10913_CR92","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ijrobp.2009.09.064","volume":"76","author":"SC Darby","year":"2010","unstructured":"Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, Mabuchi K, Marks LB, Mettler FA, Pierce LJ, Trott KR, Yeh ETH, Shore RE (2010) Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76(3):656\u2013665. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.09.064","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10913_CR93","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.radonc.2009.05.021","volume":"92","author":"NS Russell","year":"2009","unstructured":"Russell NS, Hoving S, Heeneman S, Hage JJ, Woerdeman LAE, de Bree R, Lohuis PJFM, Smeele L, Cleutjens J, Valenkamp A, Dorresteijn LDA, Dalesio O, Daemen MJ, Stewart FA (2009) Novel insights into pathological changes in muscular arteries of radiotherapy patients. Radiother Oncol 92(3):477\u2013483. https:\/\/doi.org\/10.1016\/j.radonc.2009.05.021","journal-title":"Radiother Oncol"},{"issue":"7","key":"10913_CR94","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1161\/CIRCULATIONAHA.105.593442","volume":"114","author":"BA Golomb","year":"2006","unstructured":"Golomb BA, Dang TT, Criqui MH (2006) Peripheral arterial disease: Morbidity and mortality implications. Circulation 114(7):688\u2013699. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.593442","journal-title":"Circulation"},{"key":"10913_CR95","doi-asserted-by":"publisher","unstructured":"Palazzo A, Ciccarese C, Iacovelli R, Cannizzaro MC, Stefani A, Salvatore L, Bria E, Tortora G (2023) Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis. ESMO Open 8(2):101154. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101154","DOI":"10.1016\/j.esmoop.2023.101154"},{"issue":"4","key":"10913_CR96","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL (2019) Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 20(4):e213\u2013e222. https:\/\/doi.org\/10.1016\/S1470-2045(18)30786-1","journal-title":"Lancet Oncol"},{"key":"10913_CR97","doi-asserted-by":"publisher","first-page":"851246","DOI":"10.3389\/fphar.2022.851246","volume":"13","author":"X Tian","year":"2022","unstructured":"Tian X, Chen L, Gai D, He S, Jiang X, Zhang N (2022) Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS. Front Pharmacol 13:851246. https:\/\/doi.org\/10.3389\/fphar.2022.851246","journal-title":"Front Pharmacol"},{"key":"10913_CR98","doi-asserted-by":"publisher","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, M\u0105dry R, Christensen RD, Berek JS, D\u00f8rum A, Tinker AV, du Bois A, Gonz\u00e1lez-Mart\u00edn A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16\/NOVA Investigators (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New Engl J Med 375(22):2154\u20132164. https:\/\/doi.org\/10.1056\/NEJMoa1611310","DOI":"10.1056\/NEJMoa1611310"},{"issue":"7","key":"10913_CR99","doi-asserted-by":"publisher","first-page":"4942","DOI":"10.1007\/s12035-017-0591-6","volume":"54","author":"J London","year":"2017","unstructured":"London J, Rouch C, Bui LC, Assayag E, Souchet B, Daubigney F, Medjaoui H, Luquet S, Magnan C, Delabar JM, Dairou J, Janel N (2017) Overexpression of the DYRK1A gene (dual-specificity tyrosine phosphorylation-regulated kinase 1A) induces alterations of the serotoninergic and dopaminergic processing in murine brain tissues. Mol Neurobiol 54(7):4942\u20134952. https:\/\/doi.org\/10.1007\/s12035-017-0591-6","journal-title":"Mol Neurobiol"},{"issue":"3","key":"10913_CR100","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00280-019-03774-w","volume":"84","author":"K Moore","year":"2019","unstructured":"Moore K, Chan JK, Alvarez Secord A, Patel MR, Callahan T, Guo W, Zhang Z-Y (2019) Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Cancer Chemother Pharmacol 84(3):635\u2013644. https:\/\/doi.org\/10.1007\/s00280-019-03774-w","journal-title":"Cancer Chemother Pharmacol"},{"key":"10913_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2024.12.008","author":"BA Maiorano","year":"2024","unstructured":"Maiorano BA, Catalano M, Mercinelli C, Cigliola A, Tateo V, Agarwal N, Gupta S, Roviello G, Necchi A (2024) Incidence and risk of thromboembolic and cardiovascular adverse events with PARP inhibitor treatment in patients with metastatic castration-resistant prostate cancer: a systematic review and safety meta-analysis. Eur J Surg Oncol. https:\/\/doi.org\/10.1016\/j.euros.2024.12.008","journal-title":"Eur J Surg Oncol"},{"issue":"5502","key":"10913_CR102","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291(5502):319\u2013322. https:\/\/doi.org\/10.1126\/science.291.5502.319","journal-title":"Science"},{"issue":"8","key":"10913_CR103","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/intimm\/dxq026","volume":"22","author":"J Wang","year":"2010","unstructured":"Wang J, Okazaki I-M, Yoshida T, Chikuma S, Kato Y, Nakaki F, Hiai H, Honjo T, Okazaki T (2010) PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol 22(8):643\u2013651. https:\/\/doi.org\/10.1093\/intimm\/dxq026","journal-title":"Int Immunol"},{"issue":"11","key":"10913_CR104","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1080\/17425255.2016.1216976","volume":"12","author":"TC Longoria","year":"2016","unstructured":"Longoria TC, Tewari KS (2016) Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol 12(11):1269\u20131277. https:\/\/doi.org\/10.1080\/17425255.2016.1216976","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10913_CR105","doi-asserted-by":"publisher","unstructured":"Chen D-Y, Huang W-K, Wu VC-C, Chang W-C, Chen J-S, Chuang C-K, Chu P-H (2019) Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a review when cardiology meets immuno-oncology. J Formos Med Assoc 118(12):1563\u20131572. https:\/\/doi.org\/10.1016\/j.jfma.2019.07.025","DOI":"10.1016\/j.jfma.2019.07.025"},{"issue":"16","key":"10913_CR106","first-page":"1445","volume":"14","author":"MA Hassan","year":"2022","unstructured":"Hassan MA, Telvizian T, Abohelwa M, Mukherji D, Skouri H (2022) Cardiac risk factors and events in patients with prostate cancer commencing androgen deprivation therapy: analysis from a tertiary care centre in the Middle East. Ecancermedicalscience 14(16):1445","journal-title":"Ecancermedicalscience"},{"key":"10913_CR107","doi-asserted-by":"publisher","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [published correction appears in Eur Heart J Cardiovasc Imaging. 2023 May 31;24(6):e98.  https:\/\/doi.org\/10.1093\/ehjci\/jead080.]. Eur Heart J Cardiovasc Imaging 23(10):e333-e465.https:\/\/doi.org\/10.1093\/ehjci\/jeac106","DOI":"10.1093\/ehjci\/jeac106"},{"issue":"6","key":"10913_CR108","doi-asserted-by":"publisher","first-page":"450","DOI":"10.7861\/clinmed.2019.0241","volume":"19","author":"AM Bougeard","year":"2019","unstructured":"Bougeard AM, Moore J (2019) Delivering perioperative care in integrated care systems. Clin Med (Lond) 19(6):450\u2013453. https:\/\/doi.org\/10.7861\/clinmed.2019.0241","journal-title":"Clin Med (Lond)"},{"issue":"6","key":"10913_CR109","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fcvm.2019.00069","volume":"4","author":"K Pinckard","year":"2019","unstructured":"Pinckard K, Baskin KK, Stanford KI (2019) Effects of exercise to improve cardiovascular health. Front Cardiovasc Med 4(6):69","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10913_CR110","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/ph15020151.PMID:35215263;PMCID:PMC8877351","volume":"15","author":"Y Morofuji","year":"2022","unstructured":"Morofuji Y, Nakagawa S, Ujifuku K, Fujimoto T, Otsuka K, Niwa M, Tsutsumi K (2022) Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer. Pharmaceuticals (Basel) 15(2):151. https:\/\/doi.org\/10.3390\/ph15020151.PMID:35215263;PMCID:PMC8877351","journal-title":"Pharmaceuticals (Basel)"},{"key":"10913_CR111","doi-asserted-by":"publisher","unstructured":"Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J, Pratt N, Reich CG, Madigan D, You SC, Ryan PB, Hripcsak G (2021) Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension 78(3). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16667","DOI":"10.1161\/HYPERTENSIONAHA.120.16667"},{"issue":"3","key":"10913_CR112","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41569-021-00611-7","volume":"19","author":"RS Taylor","year":"2022","unstructured":"Taylor RS, Dalal HM, McDonagh STJ (2022) The role of cardiac rehabilitation in improving cardiovascular outcomes. Nat Rev Cardiol 19(3):180\u2013194","journal-title":"Nat Rev Cardiol"},{"issue":"26","key":"10913_CR113","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1200\/JCO.2011.35.1494","volume":"29","author":"S Punnen","year":"2011","unstructured":"Punnen S, Cooperberg MR, Sadetsky N, Carroll PR (2011) Androgen deprivation therapy and cardiovascular risk. J Clin Oncol 29(26):3510\u20133516","journal-title":"J Clin Oncol"},{"key":"10913_CR114","doi-asserted-by":"publisher","unstructured":"Merseburger AS, Bakshi G, Chen DY (2024) Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network. World J Urol. 2024;42(1):156. https:\/\/doi.org\/10.1007\/s00345-024-04852-2. Published 2024 Mar 14","DOI":"10.1007\/s00345-024-04852-2"},{"key":"10913_CR115","unstructured":"Apple (India) [Internet]. [cited 2025 Jan 16]. Healthcare - Apple Watch. Available from: https:\/\/www.apple.com\/in\/healthcare\/apple-watch\/. Accessed 20 Jun 2026"},{"issue":"12","key":"10913_CR116","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3390\/ijms18122563","volume":"18","author":"SP Didion","year":"2017","unstructured":"Didion SP (2017) Cellular and oxidative mechanisms associated with interleukin-6 signaling in the vasculature. Int J Mol Sci 18(12):2563","journal-title":"Int J Mol Sci"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10913-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10913-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10913-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:45:03Z","timestamp":1784011503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10913-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":116,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10913"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10913-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"680"}}